Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin e patients in Thailand

British Journal of Haematology

Volumn 122, Issue 2, 2003, Pages 305-310

  Pootrakul, Pensri ^a   Sirankapracha, Pornpan ^a   Sankote, Jongkal ^a   Kachintorn, Udom ^b   Maungsub, Wanna ^b   Sriphen, Kosit ^b   Thakernpol, Kleonphan ^b   Atisuk, Kanit ^b   Fucharoen, Suthat ^a   Chantraluksri, Udom ^a   Shalev, Oded ^c   Hoffbrand, A Victor ^d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Deferiprone; Haemoglobin E; Iron chelation; Thalassaemia intermedia

Indexed keywords

DEFERIPRONE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN E; IRON; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTHRALGIA; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE MEMBRANE; FEMALE; FERRITIN BLOOD LEVEL; FLATULENCE; GASTROINTESTINAL SYMPTOM; HOMOZYGOSITY; HUMAN; IRON CHELATION; MALE; NAUSEA; NEUTROPHIL; PRIORITY JOURNAL; THAILAND; VOMITING;

ADMINISTRATION, ORAL; ADULT; BETA-THALASSEMIA; ERYTHROCYTE MEMBRANE; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMOGLOBIN E; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MALE; MIDDLE AGED; PYRIDONES; RECEPTORS, TRANSFERRIN; THAILAND; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0038486942     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04412.x     Document Type: Article

References (17)

1. Barman Balfour, J.A. & Foster. R.H. (1999) Deferiprone: a review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseases. Drugs, 58, 553-578.
2. Breuer, W., Ronson, A., Abramov, A., Sloki, I.M., Hershko, H, & Cabantchik, Z.I. (2000) The assessment of serum non-transferrin bound iron (NTBI) in chelation therapy and iron supplementation. Blood, 95. 2975-2992.
3. Broughter, J.M., Burton, P.S., Chase, R.L., Pregenzer, J.K., Jacobsen, E.J., VanDoornik, F.J., Tustin, J.M., Ayer, D.E. & Bundy, G.L. (1988) Novel membrane localized iron chelators as inhibitors of iron-dependent lipid peroxidation. Biochemical Pharmacology, 37. 3853-3860.
4. Cook, J.D., Dallman, P.R. & Bothwell, T.H. (1985) Serum Ferritin Measurement of Iron Status. pp. 35-54. A report by the International Nutritional Anemia Consultative Group (INACG), Kansas, USA.
5. Hershko, C. & Hoffbrand, A.V. (2001) Iron chelation therapy. Reviews in Clinical Experimental Haematology, 4, 337-361.
6. International Committee for Standardization in Haematology (ICSH) (1978) Recommendation for measurement of serum iron in human blood. Recommendation for measure of total and unsaturated iron binding capacity in serum. British Journal of Haematology, 38, 281-290 and 291-294.
7. Kontoghiorghes, G.J., Aldouri, M.A., Sheppard, L. & Hoffbrand, A.V. (1987) 1,2 dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet, i. 1294-1295.
8. Link, G., Pinson, A. & Hershko, C. (1989) Iron binding modifies the fatty acid composition of cultured rat myocardial and liposomal membranes: effect of ascorbate and α tocopherol on myocardial lipid peroxidation. Journal of Laboratory and Clinical Medicine. 114. 243-249.
9. Olivieri, N.F., Koren, G., Matsui, D., Liu, P.P., Blendis, L., Cameron, R., McClelland, R.A. & Templeton, D.M. (1992) Reduction of tissue iron stores and normalization of serum ferritin during drug treatment with the oral iron chelator L1 in thalassaemia intermedia. Blood, 79, 2741-2748.
10. Ren, X., Dorrington, K.L., Maxwell, P.H. & Robbins, P.A. (2000) Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. Journal of Applied Physiology, 89, 680-686.
11. Repka, T., Shalev, O., Reddy, R., Yuan, J., Abrahamov, A., Rachmilewitz, E.A., Low, P.S. & Hebbel, R.P. (1993) Non-random association of free iron with membranes of sickle and β-thalassemic erythrocytes. Blood, 82, 3204-3206.
12. Rombos, Y., Tzanetea, R., Konstantopoulos, K., Simitzis, S., Zervas, C., Kyriaki, P., Kavouklis, M., Aessopos, A., Sakellaropoulas, N., Karagiorga, M., Kalotychou, V. & Loukopoulos, D. (2000) Chelation therapy in patients with thalassaemia using the orally active iron chelator deferiprone (L1). Haematologica, 85, 115-117.
13. Shalev, O., Repka, T., Goldfarb, A., Grinberg, L., Abrahamov, A., Olivieri, N.F., Rachmilewitz, E.A. & Hebbel, R.P. (1995) Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassaemic and sickle red blood cells in vitro and in vivo. Blood, 86, 2008-2013.
14. 14C-deferiprone in normal, thalassaemic and sickle red blood cells. British Journal of Haematology, 105, 1081-1083.
15. Smith, J.B., Ingerrnan, C.M. & Silver, M.J. (1976) Malondialdehyde formation as an indication of prostaglandin production. Journal of Laboratory and Clinical Medicine, 88, 167-172.
16. Torrance, J.D. & Bothwell, T.H. (1980) Recommended method for measurement of non-heme iron in tissues. In: Methods in Hematology-Iron (ed. by J.D. Cook), pp. 105-109. Churchill Livingstone. New York.
17. Wonke, B., Wright, C. & Hoffbrand, A.V. (1998) Combined therapy with deferiprone and desferrioxamine. British Journal of Haematology, 103, 361-364.